NCT02418585 – A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression Posted on March 1, 2021 by tsuperadmin -
NCT02417064 – A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression Posted on March 1, 2021 by tsuperadmin -
NCT01474122 – Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis Posted on December 4, 2020 by tsuperadmin -
NCT01591122 – A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Posted on October 15, 2020 by tsuperadmin -
NCT00236756 – A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome. Posted on March 26, 2020 by tsuperadmin -
NCT00236704 – Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures Posted on March 26, 2020 by tsuperadmin -
NCT00253175 – A Comparison Of The Efficacy And Safety Of Topamax® (Topiramate) Tablets Versus Placebo For The Prophylaxis Of Migraine Posted on March 26, 2020 by tsuperadmin -
NCT00230698 – Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures Posted on March 26, 2020 by tsuperadmin -
NCT00236418 – Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures Posted on February 6, 2020 by tsuperadmin -
NCT00035802 – A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension Posted on February 6, 2020 by tsuperadmin -
The YODA Project